ATE335488T1 - Kombinationstherapie mit zd6474 und einem taxan - Google Patents

Kombinationstherapie mit zd6474 und einem taxan

Info

Publication number
ATE335488T1
ATE335488T1 AT02772624T AT02772624T ATE335488T1 AT E335488 T1 ATE335488 T1 AT E335488T1 AT 02772624 T AT02772624 T AT 02772624T AT 02772624 T AT02772624 T AT 02772624T AT E335488 T1 ATE335488 T1 AT E335488T1
Authority
AT
Austria
Prior art keywords
taxan
combination therapy
therapy
combination
Prior art date
Application number
AT02772624T
Other languages
English (en)
Inventor
Stephen Robert Wedge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE335488T1 publication Critical patent/ATE335488T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02772624T 2001-11-08 2002-11-06 Kombinationstherapie mit zd6474 und einem taxan ATE335488T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0126879.6A GB0126879D0 (en) 2001-11-08 2001-11-08 Combination therapy

Publications (1)

Publication Number Publication Date
ATE335488T1 true ATE335488T1 (de) 2006-09-15

Family

ID=9925430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02772624T ATE335488T1 (de) 2001-11-08 2002-11-06 Kombinationstherapie mit zd6474 und einem taxan

Country Status (22)

Country Link
US (2) US20050043395A1 (de)
EP (1) EP1446124B1 (de)
JP (1) JP4694127B2 (de)
KR (1) KR100959607B1 (de)
CN (1) CN1298328C (de)
AR (1) AR037346A1 (de)
AT (1) ATE335488T1 (de)
AU (1) AU2002337382B2 (de)
BR (1) BR0213906A (de)
CA (1) CA2464758C (de)
CY (1) CY1106259T1 (de)
DE (1) DE60213845T2 (de)
DK (1) DK1446124T3 (de)
ES (1) ES2269769T3 (de)
GB (1) GB0126879D0 (de)
IL (2) IL161744A0 (de)
MX (1) MXPA04004355A (de)
NO (1) NO328048B1 (de)
NZ (1) NZ532525A (de)
PT (1) PT1446124E (de)
WO (1) WO2003039551A1 (de)
ZA (1) ZA200403455B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL203782B1 (pl) 1999-11-05 2009-11-30 Astrazeneca Ab Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
AU779695B2 (en) 2000-04-07 2005-02-10 Astrazeneca Ab Quinazoline compounds
DK1474420T3 (da) 2002-02-01 2012-05-21 Astrazeneca Ab Quinazolinforbindelser
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
NZ539408A (en) 2002-11-04 2007-09-28 Astrazeneca Ab Quinazoline derivatives as SRC tyrosine kinase inhibitors for treating solid tumours
ATE506062T1 (de) * 2003-02-13 2011-05-15 Astrazeneca Ab Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
EP1648465B1 (de) * 2003-07-10 2010-08-25 AstraZeneca AB Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität
EP1691809A1 (de) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Kombinationstherapie mit verwendung von et-743 und paclitaxel zur behandlung von krebs
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0411378D0 (en) * 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
WO2006002422A2 (en) * 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
AU2005288737B2 (en) * 2004-09-27 2008-08-14 Astrazeneca Ab Combination comprising ZD6474 and imatinib
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
PT1971338E (pt) * 2005-12-22 2011-05-09 Astrazeneca Ab Combina??o de zd6474 e pemetrexed
US20080045589A1 (en) * 2006-05-26 2008-02-21 Susan Kelley Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
JP2010504949A (ja) * 2006-09-29 2010-02-18 アストラゼネカ アクチボラグ Ｚｄ６４７４とベバシズマブの癌療法のための組合せ
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
BRPI0912170A2 (pt) 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
WO2010061208A2 (en) * 2008-11-03 2010-06-03 Astrazeneca Ab Therapeutic treatment 555
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法
CN106478598B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种凡德他尼水合物晶体及其制备方法
KR20220090431A (ko) * 2020-12-22 2022-06-29 한미약품 주식회사 Sos1 억제제로서의 신규한 퀴나졸린 유도체 화합물 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
DE69722793T2 (de) * 1996-04-26 2004-05-19 Genaera Corp. Squalamin in kombination mit anderen antikrebs-mittelen zur behandlung von tumoren
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9727524D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
US6191290B1 (en) * 1999-02-24 2001-02-20 Uab Research Foundation Taxane derivatives for targeted therapy of cancer
ES2223705T3 (es) * 1999-04-28 2005-03-01 Board Of Regents, The University Of Texas System Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
PL203782B1 (pl) * 1999-11-05 2009-11-30 Astrazeneca Ab Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
WO2004014383A1 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
ATE506062T1 (de) * 2003-02-13 2011-05-15 Astrazeneca Ab Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11
EP1648465B1 (de) * 2003-07-10 2010-08-25 AstraZeneca AB Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität
AU2005288737B2 (en) * 2004-09-27 2008-08-14 Astrazeneca Ab Combination comprising ZD6474 and imatinib
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
PT1971338E (pt) * 2005-12-22 2011-05-09 Astrazeneca Ab Combina??o de zd6474 e pemetrexed
JP2010504949A (ja) * 2006-09-29 2010-02-18 アストラゼネカ アクチボラグ Ｚｄ６４７４とベバシズマブの癌療法のための組合せ

Also Published As

Publication number Publication date
KR20050043779A (ko) 2005-05-11
EP1446124B1 (de) 2006-08-09
IL161744A0 (en) 2005-11-20
ES2269769T3 (es) 2007-04-01
HK1068546A1 (en) 2005-04-29
CN1298328C (zh) 2007-02-07
CA2464758C (en) 2010-09-28
US20120252827A1 (en) 2012-10-04
JP4694127B2 (ja) 2011-06-08
CN1612738A (zh) 2005-05-04
NO328048B1 (no) 2009-11-16
NO20042365L (no) 2004-06-07
AU2002337382B2 (en) 2008-06-12
CY1106259T1 (el) 2011-06-08
BR0213906A (pt) 2004-08-31
GB0126879D0 (en) 2002-01-02
KR100959607B1 (ko) 2010-05-27
DE60213845T2 (de) 2007-03-29
CA2464758A1 (en) 2003-05-15
WO2003039551A1 (en) 2003-05-15
US20050043395A1 (en) 2005-02-24
AR037346A1 (es) 2004-11-03
MXPA04004355A (es) 2004-08-11
DK1446124T3 (da) 2006-11-13
NZ532525A (en) 2006-11-30
IL161744A (en) 2012-01-31
DE60213845D1 (de) 2006-09-21
JP2005511597A (ja) 2005-04-28
EP1446124A1 (de) 2004-08-18
PT1446124E (pt) 2006-12-29
ZA200403455B (en) 2005-08-29

Similar Documents

Publication Publication Date Title
DE60213845D1 (de) Kombinationstherapie mit zd6474 und einem taxan
DE60326611D1 (de) N und dergleichen
DE60212600D1 (de) Audiocodierung und decodierung
DE60222285D1 (de) Niedrigviscose kratzresistente beschichtungen mit strukturgebenden und inorganischen füllstoffen
DE60308457D1 (de) Adaptive Modulation und Kodierung
DE60235614D1 (de) Kodierung und abtastung von spritzeninformation
DE60309190D1 (de) Magnetelement mit spintransfer und mram-bauelement mit dem magnetelement
GB0116644D0 (en) Electroluminescent materials and devices
DE60228061D1 (de) Maschenware mit öffnung und herstellungsverfahren
DE60227170D1 (de) Flammwidrige harzzusammensetzung und formkörper daraus
SI1558595T1 (sl) Piperazinilni in diazapanilni benzamidi in benztioamidi
PL369510A1 (en) Spirocyclic 3-phenyl-3-substituted 4-ketolactams and 4-ketolactones
AU2003290341A8 (en) Electroluminescent materials and devices
DE60304229D1 (de) Pinselabflacher und mit Pinselabflacher ausgerüstete Zeichenvorrichtung
DE60223540D1 (de) Mundschutz und mundschutzfolie
AU2003298129A8 (en) Floor-furnace chimney and the use thereof
DE60238293D1 (de) Anschlussteil und Steckverbinder mit einem solchen Anschlussteil
DE60203475D1 (de) Drosselklappe und Drossel
AU2003302323A8 (en) A method and therapeutic platelets
DE60303601D1 (de) Abgabekopf und betätigungskopf mit einem solchen abgabekopf
AU2003298739A8 (en) Intermedin and its uses
EP1468113A4 (de) Optineurin und glaukom
AU2003231827A8 (en) Pseudo-tissues and uses thereof
PL363290A1 (en) 1k-polyurethane lacquer and use thereof
GB0224734D0 (en) Construction and elongate members therefor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1446124

Country of ref document: EP